What Aetna's Alma Rate Cut Means for Psychiatrists

On July 15, 2026, Aetna cuts what it pays clinicians who bill through Alma, and the prescriber side of the cut is worse than the headlines suggest. Every story so far covers the therapy-code change: a 53-plus-minute session (90837) will now pay the same as a 45-minute one (90834). For psychiatrists and psychiatric NPs the bigger news is the E/M side: 99215 will be paid at the 99214 rate, and physicians will be paid at the nurse practitioner rate. Stacked together, those two changes can take roughly $18,000 to $26,000 a year out of a moderately sized Aetna panel. Here is the exact math, and the three ways to respond.

What exactly is Aetna changing on July 15?

Alma notified its clinicians on May 20 that Aetna is flattening three rate differentials for claims billed through the platform, effective July 15, 2026:

Alma told providers "We disagree with these changes" and collected over 5,000 clinician survey responses within days, per reporting by Behavioral Health Business and a detailed breakdown at Navigating the Insurance Maze. Aetna's public position is that its overarching reimbursement policies have not changed. Both statements can be true at once: the change lives in the fee schedule attached to Alma's contract, while Aetna's published policy stays as it was. That distinction matters later, because it tells you where payers will push next.

The announced changes cover the standalone codes above. As of this writing, neither notice addresses whether the psychotherapy add-on codes you bill with E/M visits (90833, 90836, 90838) keep their time differentials. Log into your Alma portal and read your updated regional fee schedule rather than assuming either way.

What does the cut cost a psychiatrist, in dollars?

For a prescriber, the two E/M changes compound: every visit takes the physician-to-NP haircut, and your complex visits additionally lose the 99215 premium. Here is a worked example for a psychiatrist with 15 weekly Aetna-through-Alma visits, using illustrative rates in the range platforms have historically quoted. Your fee schedule is the real number; the formula is what transfers.

Assumptions (labeled, so you can swap in your own): 99214 at $130 and 99215 at $180 for an MD, an NP differential of 15 percent (Medicare's is exactly 15 percent; commercial differentials vary), and a 48-week year.

The formula for your own panel: (your 99215 rate minus your 99214 rate) × weekly 99215 count, plus (your MD rate minus the NP rate) × all weekly E/M visits, × your working weeks. Run it before you decide anything. For a therapist-side comparison, the historical Alma gap between 90837 and 90834 ran about $15 to $25 per session, which is a $4,800 to $14,400 annual loss at 5 to 15 weekly sessions. The prescriber stack is bigger because it hits every visit, while the therapy-code change only touches the long sessions.

If you want a sanity anchor for the complexity differential: on the 2026 Medicare fee schedule, 99215 pays roughly $50 more than 99214 nationally (both numbers are public in CMS's fee schedule lookup). Aetna just flattened that $50 to zero through Alma. On this contract, a high-complexity psychiatric visit is now worth the same as a moderate one, an MD credential is worth the same as an NP credential, and the table where that was decided has no seat for you.

Why this will spread

Three reasons to treat July 15 as the start of something rather than an isolated annoyance.

First, there is precedent. In 2024, contract renewals between Optum/UnitedHealthcare and Alma cut 90837 payouts by about $10 in states like Texas and Florida. Payers have learned that platform fee schedules are the soft target: one negotiation moves rates for tens of thousands of clinicians at once, and no individual provider has appeal rights over the platform's contract.

Second, the consolidation pressure just increased. Spring Health acquired Alma on May 1, 2026. Whatever else that means, platform economics under a B2B parent tend to prioritize network scale, which is exactly the negotiating environment where payers extract rate concessions.

Third, the professional bodies are treating it as category-level. The American Psychiatric Association and the American Psychological Association sent Aetna a joint letter urging a pause on the cuts, which is not something they do for one platform's contract housekeeping. Other platforms are currently reassuring clinicians their differentials stand. That reassurance is worth exactly as much as the next contract renewal.

Option 1: stay and push back

If your Aetna panel through Alma is a large share of your income and you are not ready to move, push back through the channels that exist. Review your updated regional fee schedule in the Alma portal so you know your actual numbers rather than the averages in news coverage. Alma has said it will bring clinician survey data to Aetna. There is also a clinical appeal angle worth discussing with your biller: flattening every complex patient to a moderate rate amounts to a blanket severity determination, and a level-of-severity underpayment appeal on specific claims may have legs where extended time or high complexity was clearly documented as medically necessary.

Do not rage-quit an annual contract on July 14. Alma's stated policy is no refunds on annual plans canceled before renewal, so a mid-term exit can cost you the remaining months while also costing you the panel.

Option 2: stay and restructure your coding

The honest version of this option is narrower than billing consultants will make it sound. The point of this cut is that the high-paying differentials are gone; there is no clever code combination that recreates them inside the same fee schedule. What restructuring actually looks like is shortening sessions and seeing more patients per week, and that has a real clinical cost for exactly the complex patients who need the longer visit. If your documentation already supports your current coding, the main change worth making is defensive: keep documenting time and complexity rigorously so your claims survive the appeals you may file, and so you have a clean record if you later negotiate anywhere else.

Option 3: treat it as your exit ramp

A rate cut you cannot appeal is useful for one thing: it forces the arithmetic you have been putting off. If you have been running Aetna patients through a platform while thinking about a cash-pay practice, this is the natural decision point, and the math is friendlier than most prescribers assume.

Prescribers who have made this exact move report a consistent pattern: when insurance stops working for a panel, roughly 60 percent of established patients choose to stay and pay out of pocket rather than start over with a new prescriber. That is a rule of thumb from real practices; your fees and your local market move it. Applied to an Aetna panel of 20, it means you keep about 12 patients paying your full fee, no platform cut, no payer determining what your time is worth, plus out-of-network superbills that recover part of the cost for patients with PPO plans.

Two mechanics matter if you go this way. First, platform arrangements are built for exactly this move: you can close to new platform patients with a toggle while you build the cash side, which is much cleaner than exiting a direct payer contract. Second, the transition is an operations problem more than a persuasion problem: patients need clear fees, a superbill for every visit, and a payment experience that does not add friction. This is the part Eureka runs for the practices on it, superbills generated automatically and cards on file charged after each visit, so the switch from copays to direct pay does not become an accounts-receivable job. The full playbook, including how to sequence the patient conversations, is in our guide to transitioning from insurance to cash-pay.

"Read a platform rate cut as contract news. You hold no appeal rights over a fee schedule negotiated between a payer and a platform, so the only rates you actually control are the ones on your own fee sheet," says David Cohen, CPA, JD, who reviewed this article. "If the annual loss clears five figures and your transition plan still works when you cut that 60 percent retention rule of thumb in half, the decision has already been made for you."

The simpler version of the same rule: run the formula above for your panel. If the annual loss is a rounding error, stay and appeal. Otherwise set a transition date and use the cut as the reason you give patients, because it is the true one. Payers have told you what the relationship is. You are allowed to answer.

This article describes reimbursement changes as publicly reported and is not billing, legal, or financial advice. Verify your own fee schedules and contract terms, and involve your biller or attorney before appealing claims or exiting a contract.